
Pain Management Drugs Market
Description
The Pain Management Drugs Market is projected to reach USD 108.24 billion by 2033, growing from USD 36.35 billion in 2023 at a compound annual growth rate (CAGR) of 4.57% over the forecast period. This market encompasses a wide range of medications designed to alleviate and manage pain, from acute to chronic conditions. It includes drugs used in various settings such as hospitals, clinics, and home care, and is prescribed for a range of conditions including arthritis, cancer, postoperative pain, and neuropathic pain. The market's expansion is driven by the increasing prevalence of pain-related disorders and the ongoing development of advanced pain management therapies.
The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.
Segments covered
By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Others)
By Indication (Arthritic Pain, Neuropathic Pain, Others)
Key players
Novartis AG
Eli Lilly & Company
Abbott Laboratories
Endo Health Solutions Inc
Purdue Pharma L.P
Pfizer Inc.
Mylan NV.
Merck & Co. Inc
Johnson & Johnson
GlaxoSmithKline Plc
The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.
Segments covered
By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Others)
By Indication (Arthritic Pain, Neuropathic Pain, Others)
Key players
Novartis AG
Eli Lilly & Company
Abbott Laboratories
Endo Health Solutions Inc
Purdue Pharma L.P
Pfizer Inc.
Mylan NV.
Merck & Co. Inc
Johnson & Johnson
GlaxoSmithKline Plc
Table of Contents
- Chapter 1. Executive Summary
- Chapter 2. Scope Of The Study
- 2.1. Market Definition
- 2.2. Scope Of The Study
- 2.2.1. Objectives of Report
- 2.2.2. Limitations
- 2.3. Market Structure
- Chapter 3. Evolve BI Methodology
- Chapter 4. Market Insights and Trends
- 4.1. Supply/ Value Chain Analysis
- 4.1.1. Raw End Users Providers
- 4.1.2. Manufacturing Process
- 4.1.3. Distributors/Retailers
- 4.1.4. End-Use Industry
- 4.2. Porter’s Five Forces Analysis
- 4.2.1. Threat Of New Entrants
- 4.2.2. Bargaining Power Of Buyers
- 4.2.3. Bargaining Power Of Suppliers
- 4.2.4. Threat Of Substitutes
- 4.2.5. Industry Rivalry
- 4.3. Impact Of COVID-19 on the Pain Management Drugs Market
- 4.3.1. Impact on Market Size
- 4.3.2. End-Use Industry Trend, Preferences, and Budget Impact
- 4.3.3. Regulatory Framework/Government Policies
- 4.3.4. Key Players' Strategy to Tackle Negative Impact
- 4.3.5. Opportunity Window
- 4.4. Technology Overview
- 12.28. Macro factor
- 4.6. Micro Factor
- 4.7. Demand Supply Gap Analysis of the Pain Management Drugs Market
- 4.8. Import Analysis of the Pain Management Drugs Market
- 4.9. Export Analysis of the Pain Management Drugs Market
- Chapter 5. Market Dynamics
- 5.1. Introduction
- 5.2. DROC Analysis
- 5.2.1. Drivers
- 5.2.2. Restraints
- 5.2.3. Opportunities
- 5.2.4. Challenges
- 5.3. Patent Analysis
- 5.4. Industry Roadmap
- 5.5. Parent/Peer Market Analysis
- Chapter 6. Global Pain Management Drugs Market, By Drug Class
- 6.1. Introduction
- 6.2. NSAIDs
- 6.3. Anesthetics
- 6.4. Anticonvulsants
- 6.5. Others
- Chapter 7. Global Pain Management Drugs Market, By Indication
- 7.1. Introduction
- 7.2. Arthritic Pain
- 7.3. Neuropathic Pain
- 7.4 Others
- Chapter 8. Global Pain Management Drugs Market, By Region
- 8.1. Introduction
- 8.2. North America
- 8.2.1. Introduction
- 8.2.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.3. Market Size and Forecast, By Country, 2023-2033
- 8.2.4. Market Size and Forecast, By Product Type, 2023-2033
- 8.2.5. Market Size and Forecast, By End User, 2023-2033
- 8.2.6. US
- 8.2.6.1. Introduction
- 8.2.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.6.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.2.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.2.7. Canada
- 8.2.7.1. Introduction
- 8.2.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.7.4. Market Size and Forecast, By Product Type, 2023-2033
- 8.2.7.5. Market Size and Forecast, By End User, 2023-2033
- 8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.3. Market Size and Forecast, By Country, 2023-2033
- 8.3.4. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.5. Market Size and Forecast, By End User, 2023-2033
- 8.3.6. Germany
- 8.3.6.1. Introduction
- 8.3.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.6.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.7. France
- 8.3.7.1. Introduction
- 8.3.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.7.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.7.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.8. UK
- 8.3.8.1. Introduction
- 8.3.8.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.8.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.8.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.9. Italy
- 8.3.9.1. Introduction
- 8.3.9.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.9.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.9.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.11. Rest Of Europe
- 8.3.11.1. Introduction
- 8.3.11.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.11.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.11.4. Market Size and Forecast, By End User, 2023-2033
- 8.4. Asia-Pacific
- 8.4.1. Introduction
- 8.4.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.3. Market Size and Forecast, By Country, 2023-2033
- 8.4.4. Market Size and Forecast, By Product Type, 2023-2033
- 8.12.28. Market Size and Forecast, By End User, 2023-2033
- 8.4.6. China
- 8.4.6.1. Introduction
- 8.4.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.6.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.7. India
- 8.4.7.1. Introduction
- 8.4.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.7.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.7.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.8. Japan
- 8.4.8.1. Introduction
- 8.4.8.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.8.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.8.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.9. South Korea
- 8.4.9.1. Introduction
- 8.4.9.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.9.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.9.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.10. Rest Of Asia-Pacific
- 8.4.10.1. Introduction
- 8.4.10.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.10.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.10.4. Market Size and Forecast, By End User, 2023-2033
- 8.5. Rest Of The World (RoW)
- 8.5.1. Introduction
- 8.5.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.5.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.5.4. Market Size and Forecast, By End User, 2023-2033
- Chapter 9. Company Landscape
- 9.1. Introduction
- 9.2. Vendor Share Analysis
- 9.3. Key Development Analysis
- 9.4. Competitor Dashboard
- Chapter 10. Company Profiles
- 10.1. Novartis AG
- 10.1.1. Business Overview
- 10.1.2. Government & Defense Analysis
- 10.1.2.1. Government & Defense – Existing/Funding
- 10.1.3. Product Portfolio
- 10.1.4. Recent Development and Strategies Adopted
- 10.1.5. SWOT Analysis
- 10.2. Eli Lilly & Company
- 10.2.1. Business Overview
- 10.2.2. Government & Defense Analysis
- 10.2.2.1. Government & Defense – Existing/Funding
- 10.2.3. Product Portfolio
- 10.2.4. Recent Development and Strategies Adopted
- 10.2.5. SWOT Analysis
- 10.3. Abbott Laboratories
- 10.3.1. Business Overview
- 10.3.2. Government & Defense Analysis
- 10.3.2.1. Government & Defense – Existing/Funding
- 10.3.3. Product Portfolio
- 10.3.4. Recent Development and Strategies Adopted
- 10.3.5. SWOT Analysis
- 10.4. Endo Health Solutions Inc
- 10.4.1. Business Overview
- 10.4.2. Government & Defense Analysis
- 10.4.2.1. Government & Defense – Existing/Funding
- 10.4.3. Product Portfolio
- 10.4.4. Recent Development and Strategies Adopted
- 10.12.28. SWOT Analysis
- 10.5. Purdue Pharma L.P
- 10.5.1. Business Overview
- 10.5.2. Government & Defense Analysis
- 10.5.2.1. Government & Defense – Existing/Funding
- 10.5.3. Product Portfolio
- 10.5.4. Recent Development and Strategies Adopted
- 10.5.5. SWOT Analysis
- 10.6. Pfizer Inc.
- 10.6.1. Business Overview
- 10.6.2. Government & Defense Analysis
- 10.6.2.1. Government & Defense – Existing/Funding
- 10.6.3. Product Portfolio
- 10.6.4. Recent Development and Strategies Adopted
- 10.6.5. SWOT Analysis
- 10.7. Mylan NV.
- 10.7.1. Business Overview
- 10.7.2. Government & Defense Analysis
- 10.7.2.1. Government & Defense – Existing/Funding
- 10.7.3. Product Portfolio
- 10.7.4. Recent Development and Strategies Adopted
- 10.7.5. SWOT Analysis
- 10.8 Merck & Co. Inc
- 10.8.1. Business Overview
- 10.8.2. Government & Defense Analysis
- 10.8.2.1. Government & Defense – Existing/Funding
- 10.8.3. Product Portfolio
- 10.8.4. Recent Development and Strategies Adopted
- 10.8.5. SWOT Analysis
- 10.9 Johnson & Johnson
- 10.9.1. Business Overview
- 10.9.2. Government & Defense Analysis
- 10.9.2.1. Government & Defense – Existing/Funding
- 10.9.3. Product Portfolio
- 10.9.4. Recent Development and Strategies Adopted
- 10.9.5. SWOT Analysis
- 10.10. GlaxoSmithKline Plc.
- 10.10.1. Business Overview
- 10.10.2. Government & Defense Analysis
- 10.10.2.1. Government & Defense – Existing/Funding
- 10.10.3. Product Portfolio
- 10.10.4. Recent Development and Strategies Adopted
- 10.10.5. SWOT Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.